Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,549 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05454371 | Investigation of Urinary Biomarkers for the Detection of Prostate Cancer(URODETECT-WP2) | withdrawn | N/A | 0 | Novosanis NVINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06050954 | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)(CARMA) | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Nov 9, 2023 |
| NCT05712941 | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | withdrawn | Phase 3 | 0 | EQRx International, Inc.INDUSTRY | 0 | Nov 3, 2023 | clinicaltrials |
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer(Rideau) | withdrawn | Phase 1 / Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT00180739 | Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future | withdrawn | Phase 4 | 0 | Imperial College LondonOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05466916 | EDITS Pilot Study for Gynecologic Cancer Survivors | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05567679 | A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer | withdrawn | Early Phase 1 | 0 | Edwin Posadas, MDOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05771896 | Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC(CARE) | withdrawn | Phase 3 | 0 | GenesisCare USAOTHER | 0 | Sep 14, 2023 | clinicaltrials |
| NCT05201001 | APX005M in Patients With Recurrent Ovarian Cancer(APX005M) | withdrawn | Phase 2 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | withdrawn | Phase 2 | 0 | Bradley A. McGregor, MDOTHER | 0 | Sep 7, 2023 | clinicaltrials |
| NCT00489710 | Talabostat in Treating Patients With Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 22, 2023 | clinicaltrials |
| NCT05098327 | Pioglitazone and Insulin Resistance in ADT | withdrawn | Phase 3 | 0 | State University of New York at BuffaloOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05365243 | A Pilot Study to Evaluate the Use of the AMMA Portable Scalp Cooling System From Cooler Heads | withdrawn | N/A | 0 | Cooler Heads Care Inc.OTHER_GOV | 1 | Aug 15, 2023 | clinicaltrials |
| NCT01555632 | Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy | withdrawn | N/A | 0 | University of NebraskaOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT00298064 | Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer | withdrawn | N/A | 0 | University of New MexicoOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05363644 | BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy | withdrawn | Phase 3 | 0 | AdventHealthOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy(ITTACC) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | withdrawn | Phase 1 | 0 | University of Southern CaliforniaOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | withdrawn | Phase 2 | 0 | St. Louis UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT04510584 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05742334 | Evaluating Return to Continence and Potency Following Radical Prostatectomy | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Jun 2, 2023 | clinicaltrials |
| NCT00771017 | Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | May 25, 2023 | clinicaltrials |
| NCT04483414 | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer | withdrawn | Phase 2 | 0 | Dana MathewsOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | May 17, 2023 | clinicaltrials |
| NCT04658849 | Insulin Resistance Following ADT for Prostate CA | withdrawn | Early Phase 1 | 0 | St. Louis UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer | withdrawn | Phase 2 | 0 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | withdrawn | Phase 1 | 0 | Syneos HealthOTHER | 0 | Apr 28, 2023 | clinicaltrials |
| NCT05107427 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma(AVENU) | withdrawn | Phase 2 | 0 | 4D pharma plcINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 14, 2023 | clinicaltrials |
| NCT05245435 | Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer | withdrawn | N/A | 0 | Medical University of ViennaOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT03122470 | Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT04797078 | US/MRI Fusion Local Anestesia TransPerineal Prostate Biopsies for Detection of Prostate Cancer(FLAPP) | withdrawn | N/A | 0 | Karolinska InstitutetOTHER | 0 | Mar 10, 2023 | clinicaltrials |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 2 | Mar 8, 2023 | clinicaltrials |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | withdrawn | — | 0 | Global BioClinicalINDUSTRY | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT05705700 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT03987568 | Characterize Tumor Hypoxia by Magnetic Resonance Imaging | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Dec 21, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | withdrawn | — | 0 | Indiana UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04742972 | Prostate PMSABR Study | withdrawn | N/A | 0 | Darren PoonOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 13, 2023source: clinicaltrials